Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS
Early-phase clinical trials demonstrate good safety and tolerability profiles of novel broadly neutralising antibodies (bNAbs) N6LS, PGDM1400LS, and PGT121.414.LS in healthy adults.
All bNAbs show extended serum half-lives (approximately 49 to 71 days), supporting less frequent dosing schedules for prophylaxis or therapy.
Subcutaneous administration is feasible with acceptable bioavailability, enhanced by formulations such as ENHANZE drug product (EDP) for N6LS.
Neutralisation activity is preserved in vivo, supporting their potential use in combination strategies to prevent or treat HIV-1 infection.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.